{"entity":{"id":"nct06520683","kind":"trial","name":"Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer","aka":["SMALLER"],"tldr":"A phase 3 trial of tislelizumab in colorectal cancer, run by Sun Yat-sen University, now recruiting.","summary":"Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer is a phase 3, randomised interventional study registered as NCT06520683 by Sun Yat-sen University, with a registry enrolment figure of 180 participants, started 2024-11-01 and due to reach its primary completion in 2027-11-01. Interventions recorded: Tislelizumab; Adjuvant chemotherapy. Conditions listed: Colorectal Cancer; Microsatellite Instability High. Primary outcome: Disease-free survival (DFS). Colorectal eligibility wording from the registry: \"* dMMR and/or MSI-H colorectal carcinoma that undergo surgical resection\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06520683","url":"https://clinicaltrials.gov/study/NCT06520683"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","msi-high-colorectal"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["tislelizumab"],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06520683","phase":"3","setting":"Short-course PD-1 Blockade As Adjuvant Treatment for High-risk Stage-II DMMR/MSI-H Colorectal Cancer","sponsor":"Sun Yat-sen University","enrolled":180,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06520683/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"msi-high-colorectal","kind":"cancer","name":"Mismatch-repair deficient (MSI-high) colorectal cancer","route":"/cancers/msi-high-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}